Innovaccer Inc., | August 05, 2022
Innovaccer Inc., the Health Cloud company, announced the expansion of its Solution Suite for ACO REACH participants. With its ACO REACH Solution Suite, Innovaccer has taken its entire portfolio of solutions that several leading ACOs across the country use, to help New Entrant ACOs and High Needs Population ACOs accelerate their transformation and advance health equity.
Since the initial launch of the ACO REACH Solution Suite in April, Innovaccer has rapidly expanded its client base to include new entrants such as UpStream, Florence Health, and many more organizations that are accelerating their transformation to value-based care. These organizations are leveraging Innovaccer’s end-to-end technology platform to build a unified data foundation, develop population health management strategies, and better engage physicians and patients.
For example, UpStream chose Innovaccer as their technology partner to get a 360-degree patient view that provides actionable insights at the point of care to help improve outcomes, employ advanced analytics to assess and predict health risks to help keep patients out of the hospital, and use clinically contextual patient engagement throughout the care continuum to help improve chronic care management and the overall patient experience.
“Traditionally, many practices don’t have the experience or resources to take on the financial risks associated with value-based care models, especially for older, higher-risk populations,” said Lucas Sahm, chief information officer at UpStream. “UpStream is deeply rooted in data, which makes partnering with Innovaccer a logical step for us because we speak the same language and have the same goal: to connect, curate, and make better use of healthcare data to improve patient outcomes, improve the patient experience, while also improving financial outcomes for providers.”
Innovaccer’s ACO REACH Solution Suite brings technology and services together to help providers jump-start and excel at this new value-based model: the Innovaccer Health Cloud’s Data Activation Platform, Innovaccer’s industry-leading population health management solution, Innovaccer’s world-class population health analytics; and Innovaccer’s comprehensive SDoH solution for identifying, understanding, and mitigating social determinants—an absolute essential for supporting health equity, access to care, and community health.
“Through ACO REACH, the CMS is paving the way for provider organizations to advance health equity through value-based care. To succeed with this new program, they need the right people, processes, and technologies to help develop, implement, and optimize their shared savings strategies. As a technology-enabled service, our enhanced ACO REACH Solutions Suite enables providers to identify and address SDoH factors, reach vulnerable populations with remote patient monitoring, identify relevant care gaps and utilization trends, predict obstacles, and assist providers and patients in optimizing outcomes. We’ve strived to include everything a provider could need in a technology-enabled solution to succeed as a REACH ACO.”
Abhinav Shashank, cofounder and CEO at Innovaccer
Innovaccer has a proven history of helping health organizations succeed under risk-bearing, value-based care models. Reach out to an Innovaccer representative today to get a demo of the Innovaccer® Health Cloud’s Data Activation Platform or to find out how we are helping provider partners like you with the tools they need to reach underserved patients, identify and address SDoH, and progress in the movement toward health equity. For more information, please visit https://innovaccer.com/accelerators/aco-reach.
Innovaccer Inc., the Health Cloud company, is dedicated to accelerating innovation in healthcare. The Innovaccer® Health Cloud unifies patient data across systems and care settings, and empowers healthcare organizations to develop scalable, modern applications that improve clinical, financial, and operational outcomes. Innovaccer’s solutions have been deployed across more than 1,600 care settings in the U.S., enabling more than 96,000 providers to transform care delivery and work collaboratively with payers and life sciences companies. Innovaccer has helped its customers unify health records for more than 39 million people and generate over $1B in cumulative cost savings. Innovaccer is the #1 rated Data and Analytics Platform by KLAS, and the #1 rated population health technology platform by Black Book.
Indegene Inc | July 05, 2022
Indegene, a technology-led healthcare solutions provider, announced a partnership with Amwell®, a digital care delivery leader. This collaboration will facilitate life sciences organizations to connect patients to better quality care and drive better health outcomes.
Digital patient engagement has disrupted the healthcare landscape. Patients are increasingly becoming more knowledgeable and involved in their health journeys. They want personalized support solutions that are available on the go. The technology partnership between Indegene and Amwell will enable life sciences organizations to transform their patient support capabilities and engage with patients across digital, virtual, and physical mediums. It will allow Indegene to include Amwell’s digital care platform Converge™ into its end-to-end patient support framework and enable life sciences organizations to offer a personalized care model.
"Patient needs are rapidly evolving, and life sciences organizations often struggle to provide customized solutions that cater to them. By partnering with Amwell, we hope to equip life sciences organizations with customized patient engagement solutions that boost access to cutting-edge treatments and improve health outcomes,"
Nitin Raizada, Vice President, Enterprise Commercial at Indegene
This partnership will facilitate Indegene to enable life sciences organizations to drive virtual care automation and patient companionship to advance longitudinal care, behavioral health, and other specialty and chronic care segments. It will help patients access treatments they need and receive continued support to remain adherent through their health journeys.
“As the future of care becomes increasingly hybrid, we are excited to partner with Indegene to further expand access to our Amwell Converge Platform and help accelerate their path to market with access to our installed base of payer and provider customers,” said Rene Barron, VP Channel Management, Amwell. “Together with Indegene, we aim to ensure that all life sciences organizations can more easily connect patients to quality care to improve clinical and financial outcomes, as well as delight patients with personalized care experiences.”
Indegene is a technology-led healthcare solutions provider. It combines deep industry expertise with fit-for-purpose technology in an agile and scalable operating model. Many of the leading, global healthcare organizations rely on Indegene to deliver effective and efficient clinical, medical and commercial outcomes every day. From strategy to execution, Indegene enables healthcare organizations to be future ready.
Amwell is a leading digital care delivery platform in the United States and globally, connecting and enabling providers, insurers, patients, and innovators to deliver greater access to more affordable, higher quality care. Amwell believes that digital care delivery will transform healthcare. The Company offers a single, comprehensive platform to support all digital health needs from urgent to acute and post-acute care, as well as chronic care management and healthy living. With over a decade of experience, Amwell powers the digital health solutions for over 2,000 hospitals and 55 health plan partners with over 36,000 employers, covering over 80 million lives.
American Well, Amwell, SilverCloud, Conversa, Converge and Carepoint are registered trademarks or trademarks of American Well Corporation in the United States and other countries. All other trademarks used herein are the property of their respective owners.
Aktana | September 28, 2022
Aktana, the leader in intelligent customer engagement for the global life sciences industry, welcomes Deepak Patil as its new senior director of medical strategy. Patil comes to Aktana after leadership roles at IBM Watson Health, IQVIA, and Sun Pharma Industries where he managed medical affairs in conjunction with six key product launches and developed lasting relationships with key opinion leaders in targeted therapeutic areas. At Aktana, Patil will lead the company’s medical affairs program, initially helping to build modern, data-driven solutions for medical science liaisons but over time, also expand to other areas within medical affairs.
Medical Affairs is the “third strategic pillar of the pharmaceutical organization alongside R&D and commercial, as science and data merge,” according to a McKinsey report. Business models are starting to evolve both around and beyond the “product” to encompass the wider therapeutic context, while organizations seek to explain and contextualize the ever more complex medical science to a diverse range of stakeholders. In outreach efforts, MSLs and commercial teams can unintentionally overlap, causing major compliance issues and frustrating doctors. Aktana’s intelligence solutions will not only help medical affairs improve key opinion leader relationships but also better orchestrate outreach to the physician community in compliance with regional engagement regulations.
“Deepak brings a unique blend of medical experience – he received his medical degree in India – plus data science and operational expertise from IQVIA and IBM. As we prioritize new, AI-driven solutions for medical affairs teams, Deepak will help expertly shape our new offerings while building a powerhouse team focused on this increasingly important area of life sciences.”
Clay Hausmann, chief revenue officer at Aktana
Aktana has also announced a strategic partnership with Envision Pharma Group, a global, technology-enabled scientific communications company operating across many areas of medical affairs. Envision and Aktana will combine their offerings to help MSLs address HCP demands for personalized scientific content and coordinated omnichannel engagement.
“Aktana is committed to enabling the medical affairs organization in a new era, and I’m excited to serve in a leadership role as part of this endeavor,” said Deepak Patil. “The real-world data is there. With the right technology, we have the power to improve the generation and dissemination of scientific insights to physicians, leading to better treatment decisions and outcomes for their patients.”
With more than 300 deployments across 50+ use cases, Aktana has been refining its commercial life sciences intelligence platform for more than a decade. More than half of the world's top-20 pharmaceutical companies rely on Aktana to coordinate and optimize personalized omnichannel engagement with HCPs. Aktana’s Contextual Intelligence 360 platform is powered by the company’s next-generation Contextual Intelligence Engine, which uses AI-driven optimization to predict the value of all potential customer experiences, then prioritize and recommend Next Best Engagements that will deliver the highest ROI.
Aktana is the category creator and leader of intelligent engagement in the global life sciences industry. By ensuring that every customer experience is tailored to individual preferences and needs, Aktana helps life science companies strengthen their relationships with healthcare providers to inspire better patient care. Today, commercial and medical teams from more than 300 brands use Aktana’s AI-enabled Contextual Intelligence Engine to coordinate and optimize personalized omnichannel engagement at scale. More than half of the top-20 global pharmaceutical companies are Aktana customers. Headquartered in San Francisco, Aktana has offices in every major biopharma region around the world.
Johnson & Johnson | September 21, 2022
Johnson & Johnson opened its San Francisco Bay Campus, a state-of-the-art Research & Development facility in the Bay Area, one of the world’s most established global hubs for innovation and entrepreneurship. The nearly 200,000 square-foot facility will house up to 400 employees, more than doubling the R&D presence of Johnson & Johnson in the Bay Area. The campus bridges key scientific and technological capabilities by co-locating Janssen R&D, Johnson & Johnson Innovation and Johnson & Johnson Technology. It will further integrate the Company into the Bay Area innovation ecosystem to strengthen and increase collaborations with innovators to accelerate growth.
“Johnson & Johnson’s expanded presence in the Bay Area affirms our commitment to combining science and technology to deliver transformative healthcare solutions. On this campus, our talented teams will use their diverse experience and expertise to tackle society’s greatest health challenges to create a better future for patients.”
Joaquin Duato, Chief Executive Officer, Johnson & Johnson
The R&D focus at the new site spans Janssen’s therapeutic areas and key functions, including emerging science and technologies for gene and RNA therapies, novel treatments and approaches for retinal and infectious diseases, and advanced data science, including artificial intelligence and machine learning. Co-locating expertise at the site will enable the expansion of the Company’s world-class discovery engine and industry-leading pipeline.
“Our new state-of-the-art science facility in the Bay Area will further strengthen our R&D capabilities and transform how we discover, develop and deliver innovative medicines faster and more efficiently. By integrating drug discovery, data science and digital health, we aim to accelerate the growth of our best-in-class portfolio and deliver better health outcomes for people worldwide,” said James Merson, Ph.D., Site Head, San Francisco Bay Campus and Global Therapeutic Area Head, Infectious Diseases, Janssen Research & Development, LLC.
The Johnson & Johnson Innovation Center in California has facilitated investments and collaborations to accelerate early-stage healthcare innovation with academic and industry partners in the Bay Area and greater California ecosystem since 2014. The San Francisco Bay Campus, along with the Company’s JLABS @ South San Francisco, will continue to enable the Company to build strong relationships with entrepreneurs, scientists and investors to support and invest in highly differentiated innovations that extend and improve lives everywhere. Additionally, given the convergence of healthcare and technology in the region, the Company will increase its focus on the Johnson & Johnson Technology organization to enhance its ability to create innovative digital solutions to advance human health.
Building on Johnson & Johnson’s long-standing commitment to use its expertise and resources to reduce the environmental footprint of its operations, the Bay Area hub is designed as a high-performance green campus, reinforcing the Company’s pledge to be responsible stewards in creating a healthy, more sustainable future. The aim is for the new site to receive Silver Leadership in Energy & Environmental Design (LEED) certification, the most widely used green building rating system in the world.
About Johnson & Johnson
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 135 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly-based healthcare company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.
About the Janssen Pharmaceutical Companies of Johnson & Johnson
At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular, Metabolism & Retina; Immunology; Infectious Diseases & Vaccines; Neuroscience; Oncology; and Pulmonary Hypertension. Learn more at www.janssen.com. Follow us at @JanssenGlobal. Janssen Research & Development, LLC is part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
About Johnson & Johnson Innovation
Johnson & Johnson Innovation LLC works across the pharmaceutical, medical device and consumer health sectors to accelerate early-stage, transformational solutions by catalyzing the best ideas, wherever they are in the world. We do this by harnessing our deep scientific capabilities coupled with a wide range of tools, including customized deal structures, company creation, incubation and startup services, capital investments and other innovative business models that aim to meet the diverse needs of entrepreneurs, scientists, and emerging companies. Our goal is to help life science and health technology innovations thrive through collaboration and partnership with the global ecosystem, so that together we can change the trajectory of human health.
About Johnson & Johnson Technology
Johnson & Johnson Technology solves big problems in healthcare through technology and digital innovation. Just as doctors use scalpels, we use data science, algorithms, artificial intelligence, robotics, and other digital solutions to transform patients’ lives. From guiding patients through treatment to accelerating vaccine development to enabling employees to work seamlessly from any location, our digital tools infuse our products with novelty, dexterity, and ease.